189283-51-0Relevant articles and documents
INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
-
Paragraph 00278, (2019/08/29)
The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
Polyfluorinated salicylic acid derivatives as analogs of known drugs: Synthesis, molecular docking and biological evaluation
Shchegol'kov,Trefilova,Borisevich,Shchur,Ljushina,Khursan,Burgart, Ya.V.,Solodnikov, S.Yu.,Saloutin,Markova,Maslova,Krasnykh
, p. 91 - 99 (2016/12/22)
We have developed the convenient methods for synthesis of polyfluorosalicylic acids and their derivatives. For the first time the biological properties of polyfluorosalicylates were investigated in vitro (permeability through the biological membranes, COX-1 inhibitory action) and in vivo (anti-inflammatory, analgesic activities, acute toxicity). Molecular docking of polyfluorinated salicylates confirmed in vitro and in vivo experiments.
Design, synthesis and anticancer activity of functionalized spiro-quinolines with barbituric and thiobarbituric acids
Bhaskarachar, Ravi Kiran,Revanasiddappa, Vijayakumar G.,Hegde, Subramanya,Balakrishna, Janardhana P.,Reddy, Suman Y.
, p. 3516 - 3528 (2015/08/03)
A new series of spiro-quinoline compounds have been accomplished by the reaction of barbituric acid or thiobarbituric acid with derivatives of benzisoxazole-5-carbaldehyde or 2-substituted benzaldehyde. These compounds were evaluated for their in vitro cy
